With earnings season now here, I have been looking at what analysts are expecting from many popular companies this month.
You can see previous earnings previews on Qantas Airways Limited (ASX: QAN) and Telstra Corporation Ltd (ASX: TLS) here and here, respectively.
Today I thought I would turn my attention to biotherapeutics giant CSL Limited (ASX: CSL).
What is expected from CSL in FY 2020?
CSL is scheduled to release its full year results for FY 2020 on 19 August 2020.
According to a note out of Goldman Sachs, its analysts expect CSL to report revenue of US$9,276 million and earnings before interest and tax (EBIT) of US$2,705 million. This represents year on year growth of 8.6% and 8%, respectively.
And on the bottom line, the broker is forecasting net profit after tax growth of 6.25% to US$2,141 million and earnings per share of US$4.56.
What else should you look out for?
Plasma collections will be an important topic for management to cover with this release. There are concerns that the pandemic is weighing on collections, which could lead to higher production costs for key therapies in FY 2021.
It is because of these concerns that the CSL share price is trading well off its 52-week high at present.
Goldman Sachs believes greater clarity on this topic could narrow a valuation deficit. (The broker has a buy rating and $326.00 price target on its shares.)
Goldman commented: “Contrary to some domestic peers, CSL is negatively exposed to spread of the virus in the US. As such, relative to the sector, CSL is at its cheapest level in >5 years. Whilst we understand the nature of the concerns, we incorporate them directly and believe the quality and growth profile still stacks up better than most.”
“In our view, a HSD+ growth profile remains intact, and the degree of underperformance has more than adequately incorporated the risks. We believe a -40% decline in collection from 1 Apr-31 Dec should only be considered a low probability tail risk event, and we look to the upcoming results season to provide insights.”
Should you invest?
I agree with Goldman Sachs on CSL and believe the recent share price weakness has created a buying opportunity for investors.
And with the worst-case scenario seemingly priced into its shares already, it looks like an opportune time to invest.
5 stocks under $5
We hear it over and over from investors, “I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I’d be sitting on a gold mine!” And it’s true.
And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!
*Extreme Opportunities returns as of June 5th 2020
More reading
- Afterpay and Qantas were among the most traded shares on the ASX last week
- Buy these outstanding ASX 50 shares for strong potential returns
- Earnings season: What to expect from the Qantas FY 2020 result
- Why I would buy and hold CSL and these ASX healthcare shares
- Earnings season: What to expect from Telstra in FY 2020
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia owns shares of and has recommended Telstra Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post Earnings season: What to expect from the CSL FY 2020 result appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/3i4FV83
Leave a Reply